Compare IRWD & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRWD | BCAL |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 637.5M |
| IPO Year | 2009 | 2020 |
| Metric | IRWD | BCAL |
|---|---|---|
| Price | $3.57 | $19.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 2.0M | 141.4K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | ★ 1400.00 | 777.27 |
| EPS | 0.24 | ★ 0.42 |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | N/A |
| Revenue Next Year | $4.39 | $6.67 |
| P/E Ratio | ★ $14.73 | $46.31 |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.66 | $14.30 |
| 52 Week High | $5.78 | $20.47 |
| Indicator | IRWD | BCAL |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 58.53 |
| Support Level | $3.08 | $17.97 |
| Resistance Level | $3.95 | $19.91 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 67.44 | 82.69 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.